Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting basal-like breast cancers.

Current drug targets - 1 Nov 2012

Dey Nandini, Smith Brian R, Leyland-Jones B

Abstract excerpt

Basal-like breast tumors and triple negative breast tumors are high-risk breast cancers that typically carry the poorest prognoses compared with HR (Hormone Receptor)-positive tumors and HER2 (Human Epidermal growth factor Receptor 2)-amplified tumors for known therapies. These subsets of breast cancers exhibit aggressive clinical behavior, pushing margins of invasion, poor clinical outcome, and derive limited...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Molecular Targeted Therapy
Share to Poly(ADP-ribose) Polymerase Inhibitors
Share to Poly(ADP-ribose) Polymerases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Precision Medicine

Share to Proteomics

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Source

Identifiers

PMID: 22974394
DOI: 10.2174/138945012803530116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting basal-like breast cancers.PMID 22974394Read ↗

Basal breast cancer: a complex and deadly molecular subtype.Semantic proximity Read ↗

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancerSemantic proximity Read ↗

Triple negative breast cancer: looking for the missing link between biology and treatments.Semantic proximity Read ↗

Triple-negative breast cancer: unique biology and its management.Semantic proximity Read ↗

Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted TherapiesSemantic proximity Read ↗

Triple-negative breast cancer and the need for new therapeutic targets.Semantic proximity Read ↗

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of researchSemantic proximity Read ↗

Triple-negative breast cancer: from none to multiple therapeutic targets in two decadesSemantic proximity Read ↗

What Is the Difference Between Triple-Negative and Basal Breast Cancers?Semantic proximity Read ↗

Divide and Conquer—Targeted Therapy for Triple-Negative Breast CancerSemantic proximity Read ↗

Triple-negative breast cancer: current state of the art.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.